N
TLIS

Nuveen’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Nuveen’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,587
Closed -$82K – 3534
2022
Q1 		$82K Buy
3,587
+235
+7% +$8.13K ﹤0.01% 3254
2021
Q4 		$186K Sell
3,352
-280
-8% -$20.9K ﹤0.01% 3240
2021
Q3 		$392K Buy
3,632
+961
+36% +$128K ﹤0.01% 3214
2021
Q2 		$442K Buy
2,671
+1,243
+87% +$211K ﹤0.01% 3179
2021
Q1 		$275K Buy
+1,428
New +$356K ﹤0.01% 3189

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen's TLIS Position: Q2 2022 in Review

Nuveen sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q2 2022, closing a stake of 3,587 shares — an estimated $82K sold.

Nuveen first reported a position in TLIS in Q1 2021 and held it in 5 quarters. The position peaked at $442K in Q2 2021. 35 funds tracked by Wall St. Rank hold TLIS as of Q2 2022.

  • Nuveen reported no remaining Talis Biomedical Corporation Common Stock position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 3,587 Talis Biomedical Corporation Common Stock shares in Q2 2022, an estimated $82K.
  • Nuveen first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 5 quarters.
  • Nuveen's Talis Biomedical Corporation Common Stock position peaked at $442K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.